IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors
Portfolio Pulse from Charles Gross
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) and Amgen (NASDAQ:AMGN) have announced the start of a Phase 1/2 clinical trial evaluating the combination of IDE397 and AMG 193 in patients with MTAP deletion tumors. The trial is sponsored by Amgen and focuses on NSCLC.
August 04, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen is sponsoring a clinical trial in partnership with IDEAYA Biosciences, which could potentially lead to new treatment options and revenue streams.
The start of a clinical trial is a positive development for Amgen as it could potentially lead to the discovery of new treatment options. If successful, this could open up new revenue streams for the company.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
IDEAYA Biosciences has started a clinical trial in partnership with Amgen, which could potentially lead to new treatment options and revenue streams.
The start of a clinical trial is a positive development for IDEAYA as it could potentially lead to the discovery of new treatment options. If successful, this could open up new revenue streams for the company.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100